Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company focused on therapies for liver and viral diseases, and its news flow reflects progress across this pipeline. Company announcements frequently highlight developments in chronic hepatitis B virus (HBV) programs, obesity and metabolic dysfunction-associated steatohepatitis (MASH) research, and broader corporate activities.
News items include updates on pevifoscorvir sodium, an oral capsid assembly modulator (CAM-E) under investigation for chronic HBV infection. Aligos issues press releases on clinical trial milestones, such as the initiation and enrollment of the Phase 2 B-SUPREME study, as well as data presentations at major scientific meetings. These communications describe antiviral activity, biomarker changes, and study designs that are central to understanding the company’s HBV strategy.
Investors and observers can also find coverage of ALG-055009, a THR-β agonist being studied for obesity and MASH. News from Aligos has detailed nonclinical in vivo results in diet-induced obese mouse models, showing synergistic body weight and fat mass loss when ALG-055009 is combined with incretin receptor agonists such as semaglutide or tirzepatide. Such updates provide insight into how the company positions this candidate within emerging combination approaches in cardiometabolic disease.
Beyond pipeline data, the ALGS news stream includes corporate and financial disclosures such as quarterly business updates, financial results, inducement grants under Nasdaq Listing Rule 5635(c)(4), amendments to equity plans, and senior leadership appointments. The company also announces participation in healthcare and investor conferences, where members of management discuss strategy and development programs.
By following ALGS news, readers can track clinical progress, preclinical findings, capital and governance actions, and organizational developments that shape Aligos Therapeutics’ efforts in liver and viral disease therapeutics.
Aligos Therapeutics (Nasdaq: ALGS) reported Q3 2025 business progress and financials on Nov 6, 2025. Pevifoscorvir sodium Phase 2 B-SUPREME began dosing (first patient Aug 2025) in ~200 untreated chronic HBV subjects across the U.S., China, Hong Kong, and Canada; interim readouts are projected in 1H and 2H 2026 with topline in 2027. Phase 1 post-treatment data (96 weeks dosing) will be presented at The Liver Meeting 2025.
Cash plus investments were $99.1M at Sept 30, 2025, funding planned operations into Q3 2026. Q3 net loss was $31.5M (loss per share $(3.04)); R&D expense was $23.9M. Company is evaluating funding options including potential out-licensing for continued development.
Aligos Therapeutics (Nasdaq: ALGS) announced management will present at two investor conferences in late 2025: a Jefferies London Healthcare Conference fireside chat on November 17, 2025 at 3:00 PM GMT and a Piper Sandler 37th Annual Healthcare Conference fireside chat on December 3, 2025 at 2:00 PM ET.
Both presentations will premiere at the listed times and are accessible via the Presentation & Events section on Aligos’ Investors page at www.aligos.com. A replay of each webcast will be available for at least 30 days following the presentation.
Aligos Therapeutics (Nasdaq: ALGS) will release its third quarter 2025 financial results on Thursday, November 6, 2025 before the U.S. market opens. The company is a clinical-stage biotech focused on therapies for liver and viral diseases. Investors can expect a routine pre-market earnings release and any accompanying commentary or webcast details to be announced separately.
Aligos Therapeutics (Nasdaq: ALGS) announced on Oct 17, 2025 that its Compensation Committee granted non-qualified stock options totaling 27,400 shares as inducement awards to newly hired employees, effective Oct 15, 2025.
The awards were made under the companys 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to the closing price on the Grant Date and vest over four years with 25% vesting at the first anniversary and the remainder vesting in equal monthly installments, subject to continued employment.
Aligos Therapeutics (Nasdaq: ALGS) announced that the USAN Council has adopted pevifoscorvir sodium as the nonproprietary (generic) name for ALG-000184, an investigational therapy for chronic hepatitis B virus (HBV) infection. The name is intended to provide consistent identification and support international recognition and transparency.
The company said the name, shortened to “pevy,” is the first generic name assigned to a compound at Aligos and comes as the program advances through the ongoing Phase 2 B-Supreme study. The announcement highlights a regulatory-naming milestone rather than clinical readouts or approvals.
Aligos Therapeutics (Nasdaq: ALGS) will present at the H.C. Wainwright Liver Disease Conference on October 21–22, 2025. Members of management will deliver a company presentation covering recent clinical and corporate developments.
Investors can watch a live webcast via the Presentation & Events section on Aligos’ investor website at www.aligos.com. A replay will be available for at least 30 days after the presentation.
Aligos Therapeutics (Nasdaq: ALGS) announced eight abstracts accepted for The Liver Meeting® 2025 (Nov 7–11, 2025), including one oral presentation on 96-week and post-treatment follow-up data from the Phase 1 monotherapy study of ALG-000184, a capsid assembly modulator for chronic hepatitis B (HBV).
Highlights include an oral session on Nov 9, 2025 reporting that once-daily 300 mg ALG-000184 "demonstrates potent suppression of HBV DNA," a poster reporting sustained reduction of HBV antigen levels during an 8-week follow-up after 96 weeks of treatment, and multiple preclinical posters on CAM compounds and siRNA candidates for liver disease.
Aligos Therapeutics (Nasdaq: ALGS) announced six preclinical presentations at the 2025 International HBV Meeting in Berlin, including three oral presentations. The presentations showcase the company's research in liver and viral diseases, particularly focusing on ALG-000184 and a new antisense oligonucleotide (ASO) approach for hepatitis delta virus (HDV) treatment.
Key highlights include the first presentation of ALG-000184's direct effects in reducing HBV cccDNA in preclinical settings, supporting clinical observations of HBV antigen reductions in patients. Additionally, the company is expanding its pipeline with an ASO program for HDV treatment, targeting viral genome destruction as a potential cure strategy for HDV coinfection, which typically leads to more rapid disease progression.
Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral disease therapies, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025.
The company's management will deliver an on-demand presentation, which will be available through the Presentation & Events section on Aligos' investor relations website. The webcast recording will remain accessible for at least 30 days after the presentation.
Aligos Therapeutics (Nasdaq: ALGS) has appointed Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs. Dr. Polo brings significant experience in global regulatory affairs, particularly from his roles at Shionogi Inc. and Johnson & Johnson, where he was instrumental in the COVID-19 vaccine rollout.
Dr. Polo joins Aligos as the company advances its ALG-000184 through Phase 2 B-SUPREME study. His extensive background includes leading development teams, pharmacovigilance programs, and regulatory strategies for infectious diseases, vaccines, and global public health.